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Abstract
We sought to determine a role for platelets in in vivo angiogenesis, quantified by changes in the capillary to fibre ratio (C:F)
of mouse skeletal muscle, utilising two distinct forms of capillary growth to identify differential effects. Capillary sprouting
was induced by muscle overload, and longitudinal splitting by chronic hyperaemia. Platelet depletion was achieved by anti-
GPIba antibody treatment. Sprouting induced a significant increase in C:F (1.4260.02 vs. contralateral 1.2960.02, P,0.001)
that was abolished by platelet depletion, while the significant C:F increase caused by splitting (1.4060.03 vs. control
1.2860.03, P,0.01) was unaffected. Granulocyte/monocyte depletion showed this response was not immune-regulated.
VEGF overexpression failed to rescue angiogenesis following platelet depletion, suggesting the mechanism is not simply
reliant on growth factor release. Sprouting occurred normally following antibody-induced GPVI shedding, suggesting
platelet activation via collagen is not involved. BrdU pulse-labelling showed no change in the proliferative potential of cells
associated with capillaries after platelet depletion. Inhibition of platelet activation by acetylsalicylic acid abolished
sprouting, but not splitting angiogenesis, paralleling the response to platelet depletion. We conclude that platelets
differentially regulate mechanisms of angiogenesis in vivo, likely via COX signalling. Since endothelial proliferation is not
impaired, we propose a link between COX1 and induction of endothelial migration.
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Introduction
At least two mechanisms of new vessel formation (angiogenesis)
are now recognised, namely capillary sprouting and longitudinal
splitting [1] (Figure 1A). Sprouting angiogenesis involves ablum-
inal outgrowth, when mechanical deformation of capillaries
stimulates endothelial cell (EC) activation and proliferation.
Formation of filopodia and breakdown of the basement membrane
results in expansion of the capillary bed under reduced fluid shear
stress (FSS) [2]. Sprouting can be induced experimentally by
extirpation of a skeletal muscle, leading to overload of the
remaining synergists. In contrast, longitudinal splitting arises from
sustained increases in blood flow, which stimulates formation of
luminal lamellipodia that fuse, eventually dividing capillaries.
Experimentally, splitting angiogenesis can be induced by admin-
istration of a1-adrenoceptor antagonists, such as prazosin [3],
causing vasodilatation to chronically elevate capillary FSS. Both
forms of angiogenesis may be seen in various pathologies,
apparently determined by the local shear environment [4], but
possibly also by recruitment of endothelial mitosis that is markedly
lower in neocapillary formation by splitting. There is no
substantive difference between mouse and rat in the angiogenesis
models utilised [4]. Although platelets are implicated as mediators
of pathological angiogenesis, such as that driven by inflammation
or tumour vascularisation [5], their contribution to non-repara-
tive, physiological angiogenesis during tissue remodelling has not
been studied.
Platelet involvement is thought to be due to: (i) release of growth
factors or (ii) platelet-vessel interactions [5]. Platelets contain a-
granules, dense granules, and lysosomes. The a-granule content
includes both pro- and anti-angiogenic growth factors (including
VEGF, FGF-2, PDGF, PF4, TSP-1 and endostatin) that are
important regulators of some tumour growth [6,7]. Platelet
releasate has been linked with in vitro and in vivo angiogenesis,
involving neuropeptide Y and the angiopoietin pathway [8–10].
The mechanism of growth factor sequestration is unclear [11], but
may involve endocytosis of circulating vascular endothelial growth
factor (VEGF) or enhanced VEGF production by megakaryocytes
(the platelet precursor cells). There has been an interest in non-
haemostatic roles for platelets since the discovery that platelet
depletion prevents growth of metastases [12]. Patients with cancers
and inflammatory disorders that induce pathological angiogenesis
demonstrate higher platelet levels of growth factors, including
VEGF [13,14]. It is known that the higher VEGF levels parallels
tumour progression, and platelets are activated in the circulation
of such individuals [15]. Lystbg mice lacking dense granules and
lysosomes demonstrate normal inflammatory angiogenesis [16],
suggesting a role for a-granule release. Interestingly, pro-angio-
genic and anti-angiogenic factors may be selectively released from
platelets[17].
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Evidence supporting the need for platelet adhesion includes
unaffected in vitro endothelial tube formation in Matrigel by the
addition of platelet secretate, which includes a-granule secretions,
that is enhanced with the physical presence of platelets [18]. Also,
platelet adhesion onto tumour endothelium is accompanied by
VEGF release [19], and significantly more platelets have been
observed adherent to angiogenic vessels compared to mature
vasculature with intravital microscopy studies of dorsal skinfold
chambers [20], supporting a role for platelet-vessel interactions.
Whether platelets interact with endothelium or subendothelial
structures remains unclear. While platelets bind subendothelial
collagen after vessel injury during thrombosis, no evidence exists
for a functional role of such interactions in physiological
angiogenesis [21], nor for circulating platelet activation. Mice
lacking GPVI, of central importance to direct platelet activation
[22], demonstrate inflammatory angiogenesis in response to
subcutaneous Matrigel implantation no differently from controls
[16]. This suggests that intact collagen binding properties may not
be required for angiogenesis to occur in vivo. Thus, platelet
adhesion to endothelium may lead to angiogenesis as a result of
releasate from activated platelets, but that secretion of pro-
angiogenic factors may also occur without adhesion. For example,
quiescent platelets may more effectively stimulate wound healing
compared with activated platelets [23], possibly by enhancing
fibroblast differentiation [24]. We therefore sought to identify a
role for platelets using two in vivo models of physiological
angiogenesis, sprouting and splitting forms of capillary growth [1]
(Figure 1A), by examining the effect of platelet depletion by
antibody treatment and pharmacological inhibition of platelet
activation. We conclude that platelets differentially regulate
mechanisms of angiogenesis in vivo.
Materials and Methods
In vivo experimentation
All procedures were performed in accordance with the UK
Animals (Scientific Procedures) Act 1986, and approved by the
University of Birmingham Biomedical Ethical Review Sub-
committee. C57BL/6 (Charles River, Kent, UK), and MUC1-
VEGF mice age and weight matched were used between 8–10
weeks of age (n = 4–9 per group). Weights did not differ between
strains at 24.960.3 and 23.060.5 g respectively. Animals were
housed at 21uC with 12:12 h light:dark cycle and ad libitum access
to food and water. Longitudinal splitting angiogenesis was induced
by 7 days oral ad libitum administration of 50 mg/L prazosin
(Sigma, Poole, UK) a selective a1-adrenoceptor antagonist, in
drinking water [3]. Induction of endothelial sprouting was induced
by muscle overload [2]. Unilateral extirpation of alternate m.
tibialis anterior between animals causes hyperplasia and hyper-
trophy in the remaining m. extensor digitorum longus (EDL) since
the muscles are synergistic. Sampling occurred on the eighth day
after surgery. Surgery was performed by initially anaesthetising
mice with 5% isofluorane (Novartis Animal Health UK Ltd.,
Hertfordshire, UK) in O2 and sustaining anaesthesia with 2%
isofluorane in O2. Wounds of approximately 1.5 cm were sutured
using 6-0 absorbable suture. Systemic analgesic (2.5 mL/kg
buprenorphine, s.c.; Temgesic NVS, National Veterinary Services
Ltd., Stoke-on-Trent, UK) and topical antibiotic (Duplocillin LA,
NVS) were administered perioperatively. See Figure 1B-C for
protocol, and [40] for representative data in mice.
Platelet depletion by antibody administration and
pharmacological inhibition of platelet activation
Platelet depletion was achieved by single tail vein injection of
2 mg/g (4 mL/g) rat anti-mouse platelet glycoprotein Iba (GPIba)
antibody (Emfret Analytics, Wu¨rzburg, Germany) or 4 mL/g 0.5%
saline 24 h after overload or initiation of chronic vasodilatation
[25], to permit coagulation of any bleeding during surgery.
Antibody-induced platelet glycoprotein VI (GPVI) shedding was
achieved by an identical regimen with rat anti-mouse GPVI
antibody (Emfret) [26], dialysed to remove sodium azide
preservative. Granulocytes/monocytes were depleted for 48 h
with a single i.v. injection of 4 mg/g rat anti-mouse Ly6G/6C (Gr-
1) antibody (BD Biosciences, Oxfordshire, UK) [27]. At 4, 24, and
48 h,10 ml of whole blood was collected in a container containing
acid citrate dextrose anti-coagulant following tail-bleed. Whole
blood smears were generated and stained with Diff-Quik solution
(Dade Behring, Newark, USA). Smears were visualised for
presence of cells with lobed nuclei (neutrophils). Untreated
animals undergoing granulocyte/monocyte depletion underwent
exsanguination to generate smears.
Pharmacological inhibition of platelets was initially achieved by
30 mg/kg clopidogrel hydrogensulfate plus 30 mg/kg acetylsa-
licylic acid (aspirin, ASA; both from Sigma) [28] or either
compound alone were dissolved in drinking water and adminis-
tered 24 h after overload/prazosin initiation for 72 h (Figure SI in
File S1). A lower dose of 15 mg/kg ASA (LD-ASA) was
administered similarly. Adequate inhibition of cyclooxygenase
activity was demonstrated in dose-sighting experiments (Figure SII
in File S1).
Tissue sampling for immunohistochemistry and VEGF
protein quantification
Mice were killed by cervical dislocation. Muscles were
immediately dissected and divided into two. One half was snap-
frozen in liquid nitrogen for chemical analysis and the other in
Figure 1. Different forms of angiogenesis and experimental
protocols. A) Mechanisms of capillary sprouting and longitudinal
splitting. B) Extirpation induced endothelial sprouting, with anti-GPIba,
anti-Ly6G/6C or anti-GPVI administration 24 h after surgery. C) Prazosin
induced longitudinal splitting with anti-GPIba. Sampling always
occurred on the eighth day.
doi:10.1371/journal.pone.0107503.g001
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liquid nitrogen cooled isopentane (Sigma) mounted on 20 mm
cork discs with OCT embedding matrix (both Raymond Lamb,
Loughborough, UK) for sectioning. 10 mm sections for light
microscopy were cut on a Bright Clinicut microtome at 220uC
and mounted onto polysineTM slides (VWR International, Leuven,
Belgium) and allowed to air dry. Samples were stored at 280uC
and slides at 220uC.
For protein quantification, frozen tissue was powdered using a
chilled pestle and mortar under liquid nitrogen, suspended in ice-
cold lysis buffer (975 ml HEPES, 10 ml Protease Inhibitor Cocktail,
10 ml PMSF, 5 ml Na3Va4), and centrifuged at 5000 g for 20 min
at 4uC. Samples were assayed in duplicate. Mouse and human
VEGF protein (R&D Systems, Abingdon, UK), and PGF1a
(Cambridge Biosciences, UK) was measured by enzyme linked
immune sorbent assay (ELISA), according to manufacturer’s
instructions (5 animals/group). Total tissue protein concentration
was determined by Bradford assay (using Bradford reagent, Sigma)
performed in duplicate at the same time as the ELISA.
Immunohistochemistry
Slides were warmed to room temperature (RT) for 30 min and
staining performed on EDL sections fixed with 4% w/v electron
microscopy grade formaldehyde (TAAB, Berkshire, UK). Follow-
ing 365 min PBS washes capillary/sarcolemma staining used
1:100 fluorescein Griffonia simplicifolia lectin-1 (Vector Labora-
tories Inc., Burlingame, CA): PBS for 1 h at RT in the dark was
performed to permit quantification of capillary and fibre numbers
(Figure 2C). Sections were washed in PBS and mounted on a
coverslip with 1:10 Vectorshield plus DAPI: PBS (Vector
Laboratories Inc.). Sections were examined at610 magnification.
Four fields of view per section were analysed. In vivo platelet
labelling with DyLight488-labelled GPIbb (Emfret Analytics,
Wu¨rzburg, Germany) was performed by i.v. injection of 0.1 mg/
g body weight 10 min prior to tissue sampling (performed as
described above). Sections were examined at640 magnification.
Imaging was performed using a Zeiss Axioskop 2 plus fluorescent
microscope and images captured using an Axiocam MRc digital
camera and Axiovision software (Karl Zeiss, UK). Capillary and
fibre numbers were determined by counts after data blinding.
BrdU pulse-labelling
The In Situ Cell Proliferation Kit, FLUOS (Roche, Mannheim,
Germany) was used as per manufacturer’s instructions. Briefly,
animals were injected i.p. with bromo-deoxyuridine (BrdU)
labelling reagent 16 h prior to tissue sampling. Immunostaining
was also performed as instructed with the addition of 1:100
rhodamine Griffonia simplicifolia lectin-1 (Vector Laboratories
Inc., Burlingame, CA) to allow co-localisation of BrdU-labelled
cells with vascular structures. Slides were mounted using 1:10
Vectorshield plus DAPI: PBS to permit confirmation of nuclear
localisation of BrdU-labelling.
Generation of platelet-rich plasma and platelet isolation
To generate washed platelets, whole blood was taken slowly into
a syringe contained 100 ml anticoagulant acid citrate dextrose.
Blood was transferred to 1.5 ml tubes containing 200 ml 30uC
Tyrodes solution (130 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM
KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM
MgCl2) at pH7.3. The blood was mixed and microcentrifuged at
500 g for 5 min, producing platelet rich plasma (PRP). PRP and
around one third erythrocytes was removed to a new 1.5 ml tube
and centrifuged at 120 g for 6 min before removal of PRP to a
third 1.5 ml tube. To prevent aggregation 1 ml 10 mg/ml
prostacyclin was added to PRP before centrifugation at 1000 g
for 6 min. After supernatant removal, the platelet pellet was
resuspended in 200 ml Tyrodes. Platelet numbers were determined
with a Coulter counter (Beckman, High Wycombe, UK).
Flow cytometry
Whole blood was taken into a syringe containing acid citrate
dextrose anticoagulant from the inferior vena cava under 2%
isofluorane anaesthesia, which does not affect platelet function
[29,30] to generate washed platelets before flow cytometry [31].
To determine GPVI expression following anti-GPVI administra-
tion 2 ml of FITC-conjugated antibody against GPVI (Emfret
Analytics) was added to 100 ml of 16106 washed platelets
resuspended in 30uC Tyrode’s solution. Samples were rested for
30 min at RT in the dark. 200 ml PBS was added to stop the
reaction, and samples analysed immediately.
Statistical Analysis
Data are presented as Mean6SEM. Statistical analysis used
one-way ANOVA with Bonferroni post hoc analysis, * =P,0.05,
** =P,0.01, and *** =P,0.001 vs. untreated control or contra-
lateral muscle as appropriate.
Results
Platelet depletion impairs angiogenesis by capillary
sprouting but not longitudinal splitting
Administration of the anti-GPIba antibody led to a rapid loss of
circulating platelets in mice. At 24 h post injection, circulating
platelet numbers dropped to ,5% of normal values, as we and
others have previously reported [25,31] (Table SI in File S1).
Depletion was sustained for 48 h, with platelet numbers then rising
to normal levels by 5 days post treatment (data not shown). Platelet
depletion did not affect the capillary to fibre ratio (C:F) of
untreated animals, a robust means of quantifying angiogenesis
since capillary numbers increase while fibre numbers remain
consistent within a given area [32] (Figure SIII in File S1).
The first form of angiogenesis we examined was capillary
sprouting. Surgical ablation of m. tibialis anterior causes overload
of the synergist m. extensor digitorum longus (EDL), stimulating
endothelial filopodia formation by mechanotransduction of lateral
strain [1]. This represents angiogenesis under reduced fluid shear
stress (FSS) relative to prazosin-induced longitudinal splitting. The
C:F increased by 11.7% at 7 days compared to contralateral
muscles and muscles of untreated animals (P,0.001) (Figure 2A),
consistent with our previous work [1]. Anti-GPIba administration
following induction of sprouting had no significant effect on the
C:F of contralateral muscles, but prevented the increase in the C:F
of ipsilateral muscles (n.s. vs. contralateral), indicating inhibition of
sprouting angiogenesis.
Anti-GPIba administration initiates an immune response by
labelling platelets as foreign to the host, resulting in a rapid
decrease in circulating leukocyte numbers during subsequent
clearance of platelets, which had recovered by 24 h (Table SI in
File S1). To confirm inhibition of sprouting angiogenesis resulted
from platelet and not leukocyte depletion, we determined the effect
of immune cell depletion alone. Administration of anti-Ly6G/6C
causes depletion of granulocytes and monocytes lasting 48 h [27],
but had no significant effect on platelet count (depleted 2.96107
vs. control 3.36107 platelets/ml total blood) or C:F (Figure 3) of
otherwise untreated animals. Further, immune cell depletion did
not alter sprouting angiogenesis, showing a similar rise in C:F as
with untreated mice (P,0.05). These data indicate that the
reduction in immune cell numbers resulting from platelet
depletion did not contribute to the inhibition of angiogenesis.
Platelets and Angiogenesis: A Differential Effect
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Angiogenesis induced by chronic vasodilatation leads to
capillary growth through mechanotransduction of elevated FSS
[3]. Induction of longitudinal splitting led to a 9.8% higher C:F in
EDL after 7 days (P,0.01), in line with our previous work [1],
with C:F also raised following platelet depletion (P,0.05;
Figure 2B), suggesting the mechanism of longitudinal splitting
angiogenesis is platelet-independent.
Activation of platelets via COX1 but not P2Y12 is required
to promote capillary sprouting angiogenesis
Having demonstrated that the induction of sprouting angio-
genesis likely involves platelet mediation, we explored possible
mechanisms by pharmacological inhibition of platelet activation.
A combined regimen of clopidogrel hydrogensulfate with acet-
ylsalicylic acid (ASA; aspirin) at varying concentrations is used
clinically to inhibit platelet activation in order to limit thrombosis
[33]. Clopidogrel antagonises the platelet specific P2Y12 receptor.
ASA irreversibly inhibits both cyclooxygenase (COX) 1 and 2,
preventing thromboxane A2 (TXA2) and prostacyclin (PGI2)
production, although platelets express COX1 alone. Dual
clopidogrel/ASA treatment at doses of 30 mg/L for each drug
blocked capillary sprouting angiogenesis (Figure 4A), supporting
our findings with anti-GPIba administration.
To clarify the underlying mechanism we induced sprouting
angiogenesis with either clopidogrel or 30 mg/L ASA treatment
alone. Clopidogrel treatment led to capillary sprouting (19.8%
increase in C:F, P,0.01) similar to animals subjected to muscle
overload without drug administration, suggests P2Y12 signalling is
not involved in sprouting angiogenesis. However, ASA markedly
suppressed the angiogenic response to overload (Figure 4A),
suggesting inhibition of TXA2 or PGI2 was responsible for the
dual regimen inhibition of capillary sprouting.
A lower ASA dose (LD-ASA) was also investigated, as this is
likely to generate a more platelet-specific response, which showed
similar results to the higher dose ASA (Figure 4A). LD-ASA
inhibited sprouting angiogenesis (P,0.05), with no significant
difference in the C:F observed (P,0.05). Quantification of the
PGI2 breakdown product PGF1a in plasma demonstrated a
significant decrease in levels at day 7 (P,0.05) following LD-ASA
treatment with overload (Figure 4C). We are therefore unable to
distinguish between possible mediation of sprouting angiogenesis
by TXA2 or PGI2, even at lower concentrations of ASA. In
contrast to the anti-angiogenic effects, inhibition of platelet
activation with ASA is dose-dependent (Figure SII in File S1).
We also inhibited COX-mediated platelet activation by ASA
and LD-ASA from 24–96 h after initiation of longitudinal
splitting, which demonstrated no effect with platelet depletion.
ASA and LD-ASA treatment had no effect on the normal
difference seen in the C:F ratio (both P,0.05; Figure 4B),
paralleling the anti-GPIba finding and adding further support to
the hypothesis that platelets do not mediate longitudinal splitting.
Induction of longitudinal splitting had no effect on plasma levels of
PGF1a (Figure 4D), suggesting the chronic increase in FSS
sustained PGI2 levels but did not enhance them.
Increased muscle VEGF does not compensate for platelet
depletion in sprouting angiogenesis
Previous reports suggest release of growth factors from secreted
a-granules mediate pathological forms of sprouting angiogenesis
[34]. VEGF is considered a key mediator of both pathological and
physiological angiogenesis, and is contained within platelet a-
granules [15]. Thus, inhibition of capillary sprouting by platelet
depletion or inhibition could result from the absence or
impairment of local VEGF delivery. To test this hypothesis, we
determined whether tissue overexpression of VEGF compensated
for loss of platelet VEGF after platelet depletion. We used a
transgenic mouse line, MUC1-VEGF, expressing human
VEGF121 in addition to murine VEGF isoforms, resulting in
Figure 2. Platelet depletion differentially affects skeletal muscle angiogenesis. A) Capillary sprouting produced a significant capillary to
fibre ratio (C:F) increase, abolished by platelet depletion following i.p. injection of anti-GPIba(denoted by ‘-’). Depletion did not affect C:F of untreated
or contralateral limbs. B) Longitudinal splitting caused a significant increase in C:F which was unaffected by platelet depletion. *P,0.05, **P,0.01,
***P,0.001 vs. untreated. C) Detail of representative images of lectin-stained mouse muscle cross-section showing fibres (asterisks) and capillaries
(arrows) for extirpation with (i) or without (ii) platelets, and prazosin with (iii) or without (iv) platelets.
doi:10.1371/journal.pone.0107503.g002
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significantly higher VEGF levels in all tissues examined [35].
Although contribution to tissue levels of VEGF by resident
platelets is likely extremely low in the absence of adhesion, we
determined platelet [VEGF]. Levels of the murine isoform were
similar among strains, while human isoform expression was below
ELISA detection limits (Table SII in File S1).
Compared to wildtype, MUC1-VEGF EDL muscles demon-
strated ,50% higher overall (mouse + human) VEGF expression
(Figure 5A). Untreated MUC1-VEGF mice had a higher C:F than
wildtype animals (P,0.05), presumably resulting from chronic
exposure to elevated VEGF. Following induction of sprouting
angiogenesis, MUC1-VEGF mice increased the C:F ratio (P,
0.05) compared to contralateral muscles to similar levels observed
in wildtype animals (11.8% vs. 11.7% in wildtype mice). Further,
platelet depletion by anti-GPIba administration led to an
inhibition of capillary sprouting comparable to that occurring in
wildtype animals (Figure 5B). VEGF121 overexpression is therefore
unable to rescue sprouting angiogenesis following platelet deple-
tion, indicating a more substantive role for platelets than a-granule
secretion and local VEGF delivery.
Platelet mediation of capillary sprouting is independent
of collagen-induced platelet activation
Since compensation for loss of platelet VEGF did not rescue
sprouting angiogenesis we investigated whether platelet mediation
required platelet-collagen interactions, as would occur during
thrombosis, although no evidence has yet been found for collagen
exposure during capillary sprouting [21]. In vivo platelet labelling
at early (2 day) and later (7 day) stages of capillary growth
confirmed that platelets can be observed within the vasculature
(Figure 6), but were not localised to any specific element of the
neovasculature. Indeed, we could identify no difference in platelet
content of angiogenic loci between untreated and treated animals
(data not shown). However, to exclude the requirement for
activation following platelet-collagen interactions we induced
sprouting angiogenesis followed by administration of an anti-
GPVI antibody. The antibody caused shedding of about 70%
GPVI as assessed by flow cytometry analysis at 7 days (Figure 7A).
GPVI is of central importance to direct platelet activation by
collagen, irrespective of FSS level [22], but shedding did not alter
the extent of sprouting angiogenesis (C:F P,0.05 vs. contralateral
control, Figure 7B). That loss of GPVI had no effect on capillary
sprouting is consistent with the lack of an effect on pathological
angiogenesis in GPVI knockout mice [16].
Platelet depletion has no effect on proliferation of
capillary-associated cells in capillary sprouting
The total number of BrdU positive cells showed little increase
following induction of muscle overload, although this reached
statistical significance when induction of capillary sprouting
followed platelet depletion (P,0.05) this still represented only
,3% of the total nuclei content (Figure 8A). We divided total
BrdU counts into capillary-associated (endothelium, mural cells;
Figure 8B), interstitial cells (e.g. fibroblasts; Figure 8C), or
myocytes (Figure 8D) by co-localisation with rhodamine-linked
isolectin B4. The increase in BrdU labelling after capillary
sprouting resulted primarily from increased proliferation of
interstitial cells at 7 days (Figure 8E). Numbers of proliferative
capillary-associated cells were similar in sprouting angiogenesis
with or without platelet depletion (Figure 8B). These data
demonstrate that platelet depletion is not anti-angiogenic due to
impaired EC proliferation, suggesting platelets may promote
capillary sprouting via inhibition of another component of
angiogenesis such as matrix proteolysis or EC migration.
Discussion
Platelets are normally regarded as effectors of haemostasis, but
proteomic analyses suggest they may play a wider role in wound
healing, tumour growth, inflammation and regeneration [36]. Our
data show a differential role for platelets in mediating two distinct
mechanisms of in vivo angiogenesis, namely capillary sprouting
and longitudinal splitting. A failure to rescue platelet depletion by
VEGF overexpression suggests the mechanism is more complex
than a-granule secretion alone. It is difficult to directly assess
platelet granule release in vivo, and monocyte-derived VEGF may
play a role in some forms of angiogenesis [37], but these data are
consistent with VEGF levels per se (irrespective of the source) not
being responsible for angiogenesis ablation following platelet
depletion. Maintenance of angiogenesis following loss of GPVI
expression, although partial, indicates collagen-induced platelet
activation is not the primary stimulus, while BrdU pulse-labelling
suggests platelets do not affect endothelial cell (EC) proliferation.
Sprouting angiogenesis induced by muscle overload [2] causing
elevated mechanical deformation of vessels and a resulting
Figure 3. Granulocytes/monocytes do not mediate endothelial
sprouting. A) Representative whole blood smears showing lympho-
cytes (black arrows) and granulocytes/monocytes (white arrow) were
visualised in control animals. B) Following i.p. administration of anti-
Ly6G/6C antibody only lymphocytes were readily visualised at 4, 24, and
48 h. C, Granulocyte/monocyte depletion did not alter the endothelial
sprouting response normally observed (P,0.01).
doi:10.1371/journal.pone.0107503.g003
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reduction in capillary FSS [1], was abolished by platelet depletion.
In contrast, splitting angiogenesis is induced by elevated capillary
FSS [3], and was unaffected by platelet depletion. Together, these
data may suggest a shear-related response to platelet mediation of
physiological angiogenesis. It is well known that higher FSS levels
induce upregulation of vasoprotective genes in EC [38]. Indeed,
while we observed significantly decreased levels of PGF1a with
capillary sprouting there was no alteration in levels with
longitudinal splitting. An alternative hypothesis is a difference in
signalling between the angiogenic forms. For example, sprouting is
dependent on matrix metalloprotease activity [39] while both
forms require VEGF [40]. VEGF is found in both platelets and
granulocytes, particularly neutrophils [41]. However, capillary
sprouting was normal following granulocyte/monocyte depletion,
demonstrating that despite the initial fall in immune cell numbers
during platelet clearance after anti-GPIba administration, it was
depletion of platelets rather than immune cells that mediated
angiogenesis.
Inhibition of capillary sprouting following treatment with a dual
regimen of clopidogrel/ASA confirmed the platelet depletion
result. ASA was identified as the active agent at both high and low
dose regimens. The data are consistent with overload-induced
angiogenesis acting through COX signalling, and implicate COX
inhibition of TXA2 or PGI2 synthesis as the anti-angiogenic target.
Although ASA is not platelet specific, treatment may have a
greater effect on platelets than EC depending on dose treatment
regimen, since anucleate platelets are unable to initiate COX gene
transcription. In addition, EC are primarily responsible for
production of PGI2, and platelets TXA2, so that while PGI2 levels
are able to recover in this model, inhibition of TXA2 is irreversible
[42], suggesting that TXA2 may be the target molecule. Our data
suggests a graded response to different ASA doses with LD-ASA
resulting in C:F similar to untreated animals, while ASA doses
showed an increase. Further studies are required to fully define the
in vivo mechanisms involved. Splitting angiogenesis was unaffect-
ed by ASA and LD-ASA treatment, confirming this form of
angiogenesis does not require platelet mediation.
Having identified a role for platelets in physiologically-induced
sprouting angiogenesis we sought to identify whether mediation
required a-granule secretion alone or platelet-collagen interactions
as with thrombosis. Animals lacking either platelet dense granules
or lysosomes undergo angiogenesis in a manner unchanged from
controls [16], suggesting a-granules are required for mediation of
capillary sprouting. Studies into platelet mediation of pathological
Figure 4. Platelets differentially affect angiogenesis via COX signalling. A) Dual clopidogrel/ASA regimen inhibited sprouting angiogenesis.
Single regimens identified ASA as the active agent, with clopidogrel unable to alter the angiogenic response. B) Longitudinal splitting was unaffected
by ASA or lower dose (LD)-ASA. C) PGF1a dropped significantly with overload + LD-ASA. D) Induction of longitudinal splitting did not alter PGF1a
levels. *P,0.05, **P,0.01 between columns (A), or vs. untreated controls (B).
doi:10.1371/journal.pone.0107503.g004
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angiogenesis has concentrated on the role of VEGF, contained
within a-granules [15] and widely seen as the most important
growth factor to capillary growth. Indeed, endothelial sprouting is
abolished without VEGF [40].
We reasoned that if a-granule content was responsible for
mediation of capillary sprouting, compensating for the loss of
platelet-derived VEGF after depletion may rescue the angiogenic
response. We therefore induced sprouting angiogenesis in MUC1-
VEGF transgenic mice, which have tissue VEGF levels 45%
greater than wildtype mice due to expression of human VEGF121
in addition to normal mouse isoforms. Although this overexpres-
sion was not detectable in platelets, levels of murine VEGF were
similar to wildtype and hence we could detect any influence of
altered tissue concentrations. In contrast to studies showing
reliance of angiogenesis in VEGF, compensation of VEGF levels
by overexpression did not rescue capillary sprouting, which was
abolished in both wildtype and MUC1-VEGF mice with platelet
depletion. Subsequent to submission of the original manuscript,
intriguing in vitro data has suggested that platelet mediated
angiogenesis is inhibited by ASA and may be independent of
VEGF [43].
Capillary sprouting is therefore unlikely to be driven by release
of VEGF from platelet a-granules, and so we tested the hypothesis
that platelet-vessel interactions are responsible. During thrombo-
sis, platelets become activated by exposed subendothelial collagen
through GPVI. Mice with approximately 70% of GPVI shed
demonstrated capillary sprouting in a similar manner to wildtype
mice, suggesting collagen binding is not a significant mechanistic
pathway during this form of angiogenesis. Indeed, we have
previously identified no subendothelial exposure by electron
micrograph analysis [21]. Our GPVI data is consistent with data
from GPVI knockout mice implanted with subcutaneous Matrigel
to model inflammatory angiogenesis, [16], where no change was
observed.
Figure 5. VEGF overexpression cannot rescue angiogenic
deficit. A) Extensor digitorum longus muscle VEGF expression in
wildtype and MUC1-VEGF mice. MUC1-VEGF human VEGF (N) plus
mouse VEGF (#) resulted in a 45% increase in total content (&) vs.
wildtype. B) MUC1-VEGF mice had higher initial C:F than wildtype.
Capillary sprouting with or without platelets was no different from
wildtype. *P,0.05 vs. C57 BL/6 controls, +P,0.05 vs. contralateral.
doi:10.1371/journal.pone.0107503.g005
Figure 6. Platelets are observable in skeletal muscle vascula-
ture. Platelets were labelled in vivo prior to muscle sampling. A)
Imaging of muscle sections for the presence of platelets occurred under
fluorescent microscopy in conjunction with B) rhodamine Griffonia
simplicifolia lectin-1 staining for visualisation of vasculature, and C) DAPI
for localisation of nuclei. D) A merged image of the three other panels
depicts platelets within a venule, a potential locus for angiogenesis.
doi:10.1371/journal.pone.0107503.g006
Figure 7. Angiogenesis is independent of collagen-induced
platelet activation. A) Anti-GPVI resulted in ,70% GPVI shedding.
Shaded grey peak, GPVI shed; clear black peak, control; clear grey peak,
GPVI shed IgG expression. B) GPVI shedding did not alter capillary
sprouting, with significantly increased C:F. *P,0.05 vs. contralateral.
doi:10.1371/journal.pone.0107503.g007
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Our data suggests a requirement for platelets at the initiation
phase of the angiogenic response, since platelet depletion early on
inhibits angiogenesis even 5 days after platelet numbers have
normalised [25,31]. The increase in number of proliferating cells
following induction of capillary sprouting remained after platelet
depletion. Co-localisation analysis demonstrated that the labelling
index of capillary-associated cells and myocytes remained
unchanged after capillary sprouting with or without platelet
depletion. The increase in BrdU-labelling was therefore a result of
increased proliferation of interstitial cells, and indicates that
platelet depletion is not anti-angiogenic due to inhibition of EC
proliferation. It is presumed, therefore, that platelets promote
capillary sprouting via activation of another component of
angiogenesis, such as endothelial migration and/or proteolytic
modification of the extracellular matrix. In fact, inhibition of
matrix metalloproteases required for extracellular matrix break-
down abolishes sprouting angiogenesis [39]. Additionally, it is
conceivable that sphingosine-1-phosphate is required, since TXA2
Figure 8. Platelet depletion did not affect proliferation of capillary-associated cells or myocytes. A) The total number of proliferating
cells increased slightly in tissue after induction of capillary sprouting, but was not affected by platelet depletion. B) Capillary-associated cell
proliferation was unaffected by platelet depletion. C) The increase in proliferating cell number with sprouting results from increased interstitial cell
proliferation. D) The absence of platelets did not impair the proliferation of myocytes following muscle overload. E) BrdU labelling was performed in
conjunction with rhodamine Griffonia simplicifolia lectin-1 staining (bottom left panel) for visualisation of vasculature, and DAPI (top right panel) to
ensure BrdU staining observed was localised to nuclei. A merge (bottom right panel) of the three other panels with three BrdU-labelled interstitial
cells (white arrows) is shown. Imaging was performed with fluorescent light microscopy as described in the methods at640 magnification. *P,0.05
vs. contralateral.
doi:10.1371/journal.pone.0107503.g008
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synthesis and thromboxane receptor activation mediate its release,
while ASA inhibits its release [44].
In conclusion, using two distinct forms of capillary growth in
vivo we have identified differential platelet mediation of physio-
logical angiogenesis. Angiogenesis in high FSS environments is
platelet independent, whereas angiogenesis under lower FSS is
platelet mediated. Endothelial sprouting requires the presence of
platelets, but not in delivery of pro-angiogenic growth factors
released from a-granules alone, or platelet interactions with
collagen. Platelet mediation did not result from alterations in
proliferative potential of endothelium or perivascular cells, but
platelet activation via COX is fundamental to sprouting angio-
genesis.
Supporting Information
File S1 Table SI, Differential white cell count 24 h
following platelet depletion (6103.mm23). Table SII,
Platelets VEGF content is not altered by treatment (pg
VEGF.1026 platelets; mean±SEM). Figure SI, Experi-
mental protocol for inhibition of platelet activation with
clopidogrel and/or acetylsalicylic acid (ASA; aspirin). A)
Endothelial sprouting was induced by extirpation of m. tibialis
anterior causing overload of m. extensor digitorum longus. 24 h
after surgery oral 30 mg/kg clopidogrel/ASA as dual or single
regimens was administered for 72 h. B) ASA administration was
begun 24 h after initiation of prazosin treatment, lasting 72 h.
Prazosin induces longitudinal splitting. In both A and B, sampling
occurred on the eighth day. Figure SII, Inhibition of platelet
activation with acetylsalicylic acid (ASA; aspirin) is dose-
dependent. Mice were administered aspirin via drinking water
for 7 days. Experimental groups were 3 control mice, 3 low dose
aspirin mice (30 mg/litre) and 3 high dose aspirin mice (300 mg/
litre). Following 7 days aspirin treatment, blood was collected into
sodium citrate and platelet-rich plasma (PRP) was prepared by
centrifugation. Platelet aggregation was monitored by light
transmission aggregometry in a Born lumi-aggregometer. Follow-
ing stimulation with 0.5 mM arachidonic acid, platelets from the
low dose aspirin treated mice aggregated normally (A) whereas
platelets from the high dose aspirin treated mice showed only a
minimal shape change response (B). Platelets from all mice
aggregated normally to 500 mM PAR-4 peptide (C). Figure SIII,
Influence of scaling on muscle capillary supply. In
response to reviewer comments we offer an explanation for the
choice of capillary to fibre ratio (C:F) as the most robust index of
angiogenesis. It has been repeatedly been shown that other
methods of quantifying angiogenesis (such as capillary density;
Hudlicka´ O, Brown MD, Egginton S. 1992. Angiogenesis in
skeletal and cardiac muscle. Physiological Reviews 72: 369–417)
have a bias due to alterations in fibre size often observed among
experimental groups, that mask the changes in capillary number,
whereas C:F is much less sensitive to these scaling effects (Egginton
S. 1990. Morphometric analysis of tissue capillary supply. In:
Boutilier RG (ed) Vertebrate Gas Exchange from Environment to
Cell. Advances in Comparative and Environmental Physiology. 6:
73–141; Hudlicka´ O, Brown MD, Egginton S. 1998. Angiogen-
esis: basic concepts and methodology. Chapt. 1, pp 3–19. In:
Halliday A, Hunt BJ, Poston L, Schachter M (eds) An Introduction
to Vascular Biology. CUP). The current experiment is no different:
(1) contralateral muscle 6 platelet depletion show minor, but
reciprocal differences in CD and a(f). (2) extirpation without
platelet depletion has a similar CD to contralateral muscle despite
muscle hypertrophy that would be expected to reduce CD if
angiogenesis had not occurred (C:F is significantly higher); in
contrast extirpation with platelet depletion had both a similar CD
and a(f) as contralateral muscles reflecting an absence of
angiogenesis (C:F similar). (3) in the same way, relatively small
differences in fibre size explain the modest difference in CD
among prazosin groups, while the C:F is very similar (see Fig. 2 in
the main text). Abbreviations: CD, capillary density; a(f), fibre
cross-sectional area; C-, contralateral without platelet depletion;
C+, contralateral with platelet depletion; E, extirpation; P,
prazosin.
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